Avid Bioservices (NASDAQ:CDMO) Announces Earnings Results

Share on StockTwits

Avid Bioservices (NASDAQ:CDMO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05), Briefing.com reports. The business had revenue of $15.25 million for the quarter, compared to analyst estimates of $14.37 million. Avid Bioservices had a negative return on equity of 9.29% and a negative net margin of 7.86%. Avid Bioservices’s revenue was up 21.1% compared to the same quarter last year. Avid Bioservices updated its FY 2020 guidance to EPS.

Shares of NASDAQ:CDMO traded down $1.00 during trading on Friday, reaching $6.05. 176,000 shares of the stock were exchanged, compared to its average volume of 187,756. Avid Bioservices has a 12 month low of $3.37 and a 12 month high of $8.44. The firm has a market cap of $396.49 million, a PE ratio of -35.59 and a beta of 2.80. The stock has a 50-day moving average price of $6.56 and a 200-day moving average price of $4.91.

A number of equities analysts have weighed in on CDMO shares. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Avid Bioservices in a research report on Monday, July 8th. Janney Montgomery Scott upgraded Avid Bioservices from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Friday, June 28th. TheStreet upgraded Avid Bioservices from a “d” rating to a “c-” rating in a report on Tuesday, July 9th. Zacks Investment Research cut Avid Bioservices from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, ValuEngine upgraded Avid Bioservices from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $8.58.

Avid Bioservices Company Profile

Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Further Reading: How are institutional investors different from individual investors?

Earnings History for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nanometrics  Lifted to Hold at BidaskClub
Nanometrics Lifted to Hold at BidaskClub
Nasdaq  Downgraded by BidaskClub
Nasdaq Downgraded by BidaskClub
NetScout Systems  Raised to “Hold” at BidaskClub
NetScout Systems Raised to “Hold” at BidaskClub
Intellia Therapeutics  Raised to Hold at BidaskClub
Intellia Therapeutics Raised to Hold at BidaskClub
Northern Trust  Lifted to “Hold” at BidaskClub
Northern Trust Lifted to “Hold” at BidaskClub
Liberty Latin America  Upgraded at BidaskClub
Liberty Latin America Upgraded at BidaskClub


© 2006-2019 Ticker Report